Single molecule fluorescent sequencing

SeqLL Announces CRADA with the FBI

Retrieved on: 
Tuesday, February 7, 2023
Molecule, Cooperative research and development agreement, RNA, DNA, SQL, FBI, Single molecule fluorescent sequencing, Assistant director, Development, U.S. Department of Defense Strategy for Operating in Cyberspace, CRADA

Under this CRADA, SeqLL and the FBI Laboratory Division (FBI LD) will seek to evaluate and determine the forensic capabilities of direct RNA sequencing using SeqLL’s True Single Molecule Sequencing (tSMS®) platform.

Key Points: 
  • Under this CRADA, SeqLL and the FBI Laboratory Division (FBI LD) will seek to evaluate and determine the forensic capabilities of direct RNA sequencing using SeqLL’s True Single Molecule Sequencing (tSMS®) platform.
  • The FBI LD and SeqLL will collaborate with a goal of producing an assay for forensic body fluid identification, without compromising traditional STR or DNA sequence analysis.
  • This agreement is among the first times the FBI is utilizing the CRADA mechanism to further develop laboratory capabilities.
  • We appreciate the opportunity this CRADA provides, to methodically develop forensic applications utilizing SeqLL’s technology,” said Daniel Jones, SeqLL CEO and Founder.

Brian Paras joins SeqLL as Chief Business Officer

Retrieved on: 
Tuesday, December 13, 2022
Molecule, RNA, Intellectual property, Nature, Security (finance), SQL, Form, Suffolk University, Independent school district, Caliper Life Sciences, Risk, MBA, Research, Disease, Partnership, Single molecule fluorescent sequencing, Fine chemical, Management, Psychology, Science

BILLERICA, Mass., Dec. 13, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a technology company providing life sciences instrumentation and research services, today announced that Brian Paras has joined the company as Chief Business Officer.

Key Points: 
  • BILLERICA, Mass., Dec. 13, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a technology company providing life sciences instrumentation and research services, today announced that Brian Paras has joined the company as Chief Business Officer.
  • “Brian brings 30-plus years of product introduction & commercialization, global sales & marketing leadership, and key industry partnership & strategic alliance building to the company.
  • “I am thrilled to be joining the dedicated and talented people at SeqLL,” said Brian Paras.
  • SeqLL Inc. (“SeqLL”) is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple “omics” fields.

SeqLL Provides Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 10, 2022
Molecule, GLOBE, Forward-looking statement, Intellectual property, PCR, Risk, Nature, U.S. Securities and Exchange Commission, Independent school district, Accounting, Research, Private Securities Litigation Reform Act, Technology, Bias, DNA, RNA, Form, NASDAQ, Company, Disease, Security (finance), SQL, NGS, Single molecule fluorescent sequencing, COVID-19, Income, Pharmaceutical industry

BILLERICA, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (SeqLL or the Company) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services aimed at the development of novel scientific assets and intellectual property, today announced its operating and financial results for the third quarter ended September 30, 2022.

Key Points: 
  • BILLERICA, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (SeqLL or the Company) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services aimed at the development of novel scientific assets and intellectual property, today announced its operating and financial results for the third quarter ended September 30, 2022.
  • We expect to resume normal operations in the final quarter of 2022.
  • In addition, there was no grant revenue during the three months ended September 30, 2022 due primarily to 2022 being the final year of the award.
  • General and administrative expenditures will continue to increase during 2022 to support ongoing financial reporting and compliance activities.

UPDATE -- SeqLL Announces Peer-Reviewed Publication of Novel Single-Molecule Liquid Biopsy Method in Nature Biotechnology

Retrieved on: 
Tuesday, September 13, 2022
Molecule, Risk, Degenerative disease, Independent school district, DNA methylation, Department, Weizmann Institute of Science, Assistant, Disease, Hospital, Immunology, Multiplexing, Colorectal cancer, Nature, Company, Cancer, CRC, Intellectual property, Liquid, Massachusetts General Hospital, Nature Biotechnology, Forward-looking statement, U.S. Securities and Exchange Commission, Weizmann, List of life sciences, Technology, SQL, Broad Institute, Global health, Private Securities Litigation Reform Act, Diagnosis, Nucleosome, Discoveries, NASDAQ, Harvard Medical School, Death, RNA, Heart, Research, GLOBE, DNA, Security (finance), AUC, Lead, Plasma, Single molecule fluorescent sequencing, PDAC, Medical device, Fine chemical, Medical imaging, Science, News, Blood

The studys predictive model displayed high diagnostic potential by generating a 0.96 AUC, sensitivity of 92% at 85% specificity, and 92% precision when analyzing CRC samples.

Key Points: 
  • The studys predictive model displayed high diagnostic potential by generating a 0.96 AUC, sensitivity of 92% at 85% specificity, and 92% precision when analyzing CRC samples.
  • Additionally, Stage I/II CRC samples were readily distinguishable from Stage III/IV and resected Stage III/IV CRC samples.
  • Dr. Shema and Mr. Jones were the lead and second author on that publication and have continued to collaboratively develop the underlying technology.
  • The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

SeqLL Announces Peer-Reviewed Publication of Novel Single-Molecule Liquid Biopsy Method in Nature Biotechnology

Retrieved on: 
Monday, September 12, 2022
Molecule, Risk, Degenerative disease, Independent school district, DNA methylation, Department, Weizmann Institute of Science, Assistant, Disease, Hospital, Immunology, Colorectal cancer, Nature, Company, Cancer, CRC, Intellectual property, Liquid, Massachusetts General Hospital, Nature Biotechnology, Forward-looking statement, U.S. Securities and Exchange Commission, Weizmann, List of life sciences, Technology, SQL, Broad Institute, Global health, Annual report, Private Securities Litigation Reform Act, Diagnosis, Nucleosome, NASDAQ, Harvard Medical School, Death, RNA, Heart, Research, GLOBE, DNA, Security (finance), AUC, Lead, Plasma, Single molecule fluorescent sequencing, PDAC, Medical device, Fine chemical, Science, News, Blood

Additionally, Stage I/II CRC samples were readily distinguishable from Stage III/IV and resected Stage III/IV CRC samples.

Key Points: 
  • Additionally, Stage I/II CRC samples were readily distinguishable from Stage III/IV and resected Stage III/IV CRC samples.
  • Dr. Shema and Mr. Jones were the lead and second author on that publication and have continued to collaboratively develop the underlying technology.
  • SeqLL Inc. (SeqLL) is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple omics fields.
  • The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

SeqLL to Present at the H.C. Wainwright 24th Annual Global Conference

Retrieved on: 
Tuesday, September 6, 2022
Molecule, Disease, Company, CEO, Intellectual property, Research, GLOBE, SQL, Conference, Single molecule fluorescent sequencing, NASDAQ

BILLERICA, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (SeqLL or the Company) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services for collaborative partnerships, today announced that Daniel Jones, CEO of SeqLL will present a corporate overview and be available for virtual 1x1 meetings at the upcoming H.C. Wainwright 24th Annual Global Conference taking place from September 12-14, 2022.

Key Points: 
  • BILLERICA, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (SeqLL or the Company) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services for collaborative partnerships, today announced that Daniel Jones, CEO of SeqLL will present a corporate overview and be available for virtual 1x1 meetings at the upcoming H.C. Wainwright 24th Annual Global Conference taking place from September 12-14, 2022.
  • The presentation will be available on demand beginning at 7:00 am ET on Monday, September 12th.
  • SeqLL Inc. (SeqLL) is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple omics fields.
  • In sum, our experienced team works with our collaborators to develop innovative solutions tailored to the needs of each specific project.

SeqLL’s Single-Molecule Nucleosome Imaging Method Published in Peer Reviewed Cell Reports Journal

Retrieved on: 
Monday, June 13, 2022
Molecule, Glioma, Company, Intellectual property, Research, Knowledge, Neoplasm, Weizmann Institute of Science, Form, Forward-looking statement, CEO, Nature, RNA, Security (finance), Disease, Brain, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, MLL1, Risk, Master of Science, GLOBE, Immunology, Technology, SQL, Cell Reports, NASDAQ, Department, Single molecule fluorescent sequencing, Nucleosome, Genomics, Cancer, Medical imaging, Fine chemical, Science, Doctor of Philosophy

The paper, entitled: H3-K27M-mutant nucleosomes interact with MLL1 to shape the glioma epigenetic landscape, applied SeqLL developed single-molecule imaging methods to look at cell mutations associated with pediatric brain cancers.

Key Points: 
  • The paper, entitled: H3-K27M-mutant nucleosomes interact with MLL1 to shape the glioma epigenetic landscape, applied SeqLL developed single-molecule imaging methods to look at cell mutations associated with pediatric brain cancers.
  • We were thrilled to see the Shema Lab apply this technology to deepen the understanding of cancer on the cellular level.
  • This research builds upon the 2016 Science publication Single-molecule decoding of combinatorially modified nucleosomes, led by the laboratory of Dr. Bradley Bernstein.
  • In sum, our experienced team works with our collaborators to develop innovative solutions tailored to the needs of each specific project.

SeqLL Provides First Quarter 2022 Financial Results and a Corporate Update

Retrieved on: 
Friday, May 13, 2022
Molecule, CEO, DNA, Form, Company, NGS, Loss, Disease, Research, U.S. Securities and Exchange Commission, Bias, Investment, NASDAQ, Single molecule fluorescent sequencing, Private Securities Litigation Reform Act, Nature, COVID-19, Accounting, Intellectual property, Forward-looking statement, RNA, Technology, PCR, Coronavirus Scientific Advisory Board (Turkey), Independent school district, SAB, Security (finance), Risk, SQL, GLOBE, Management, Online gambling, Pharmaceutical industry

Each leader has previously utilized the tSMS platform and will leverage their expertise to provide valuable insight to our company.

Key Points: 
  • Each leader has previously utilized the tSMS platform and will leverage their expertise to provide valuable insight to our company.
  • General and administrative expenditures will continue to increase during 2022 to support ongoing financial reporting and compliance activities.
  • We recognized $51,816 in net realized and unrealized losses on the marketable securities during the three-month period ended March 31, 2022.
  • The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

SeqLL Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update

Retrieved on: 
Wednesday, March 30, 2022
Molecule, Company, NASDAQ, Private Securities Litigation Reform Act, DNA, Form, Forward-looking statement, PCR, Interest, Research, Risk, NGS, Coronavirus Scientific Advisory Board (Turkey), Independent school district, CEO, Single molecule fluorescent sequencing, RNA, U.S. Securities and Exchange Commission, Bias, Technology, COVID-19, Intellectual property, GLOBE, Income, SAB, Nature, IPO, SQL, Disease, Security (finance), Animal

We are pleased with our progress across multiple developmental programs around novel asset creation using SeqLLs platform, said Daniel Jones, CEO, President, and Co-Founder of SeqLL.

Key Points: 
  • We are pleased with our progress across multiple developmental programs around novel asset creation using SeqLLs platform, said Daniel Jones, CEO, President, and Co-Founder of SeqLL.
  • Each leader has previously utilized the tSMS platform and will leverage their expertise to provide valuable insight to our company.
  • Total revenues for the year ended December 31, 2021 were $0.21 million compared to $0.33 million during the year ended December 31, 2020, representing a decrease of 36%.
  • The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

SeqLL to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest

Retrieved on: 
Thursday, March 24, 2022
Molecule, Intellectual property, GLOBE, Company, Event, Research, NASDAQ, SQL, Conference, Disease, CEO, Single molecule fluorescent sequencing

BILLERICA, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (SeqLL or the Company) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services for collaborative partnerships, today announced that Daniel Jones, CEO of SeqLL will participate at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, taking place on March 28-30, 2022.

Key Points: 
  • BILLERICA, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (SeqLL or the Company) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services for collaborative partnerships, today announced that Daniel Jones, CEO of SeqLL will participate at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, taking place on March 28-30, 2022.
  • The presentation will be available on demand beginning at 9:00 am ET on Monday, March 28th.
  • The archived webcast will also be available on the Companys investor relations website on the Events & Presentations page.
  • In sum, our experienced team works with our collaborators to develop innovative solutions tailored to the needs of each specific project.